ES2178000T3 - Composiciones y metodos para tratar infecciones usando analogos de indolicidina. - Google Patents

Composiciones y metodos para tratar infecciones usando analogos de indolicidina.

Info

Publication number
ES2178000T3
ES2178000T3 ES97941352T ES97941352T ES2178000T3 ES 2178000 T3 ES2178000 T3 ES 2178000T3 ES 97941352 T ES97941352 T ES 97941352T ES 97941352 T ES97941352 T ES 97941352T ES 2178000 T3 ES2178000 T3 ES 2178000T3
Authority
ES
Spain
Prior art keywords
compositions
methods
indolicidine
analogs
treat infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97941352T
Other languages
English (en)
Spanish (es)
Inventor
Janet R Fraser
Michael H P West
Timothy J Krieger
Robert Taylor
Douglas Erfle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biowest Therapeutics Inc
Original Assignee
Micrologix Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micrologix Biotech Inc filed Critical Micrologix Biotech Inc
Application granted granted Critical
Publication of ES2178000T3 publication Critical patent/ES2178000T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES97941352T 1996-08-21 1997-08-21 Composiciones y metodos para tratar infecciones usando analogos de indolicidina. Expired - Lifetime ES2178000T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2475496P 1996-08-21 1996-08-21
US3494997P 1997-01-13 1997-01-13

Publications (1)

Publication Number Publication Date
ES2178000T3 true ES2178000T3 (es) 2002-12-16

Family

ID=26698836

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97941352T Expired - Lifetime ES2178000T3 (es) 1996-08-21 1997-08-21 Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
ES01119148T Expired - Lifetime ES2315252T3 (es) 1996-08-21 1997-08-21 Composiciones y metodos para tratar infecciones usando analogos de indolicidina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01119148T Expired - Lifetime ES2315252T3 (es) 1996-08-21 1997-08-21 Composiciones y metodos para tratar infecciones usando analogos de indolicidina.

Country Status (9)

Country Link
US (4) US6180604B1 (enExample)
EP (1) EP0925308B1 (enExample)
JP (2) JP2001500477A (enExample)
AT (2) ATE410441T1 (enExample)
CA (1) CA2263799A1 (enExample)
DE (2) DE69713112T2 (enExample)
ES (2) ES2178000T3 (enExample)
HK (1) HK1043475B (enExample)
WO (1) WO1998007745A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910820A1 (en) * 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers
US6303575B1 (en) * 1998-05-12 2001-10-16 The Regents Of The University Of California Indolicidin analogs and methods of using same
AU4253799A (en) * 1998-06-12 2000-01-05 Micrologix Biotech, Inc. Cancer therapy with cationic peptides
US6444645B1 (en) * 1998-06-18 2002-09-03 The Regents Of The University Of California Crosslink-stabilized indolicidin analogs
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
WO2000026344A1 (en) * 1998-10-30 2000-05-11 Interlink Biotechnologies Llc Peptides with enhanced stability to protease degradation
US6946261B1 (en) * 1998-11-20 2005-09-20 Migenix Inc. Efficient methods for producing anti-microbial cationic peptides in host cells
AU782306B2 (en) * 1999-03-03 2005-07-21 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6429211B1 (en) * 2000-05-23 2002-08-06 Bayer Corporation Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora
CA2412011A1 (en) 2000-06-16 2001-12-27 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
CA2426187C (en) 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
DK1353647T3 (da) 2000-12-27 2011-06-14 Gilead Sciences Inc Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7115572B2 (en) * 2001-03-29 2006-10-03 Council Of Scientific And Industrial Research Indolicidin analogs with anti-microbial activity
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1401478A2 (en) * 2001-06-22 2004-03-31 The Hospital for Sick Children Antimicrobial peptides
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US6734165B2 (en) * 2001-08-23 2004-05-11 The Trustees Of Columbia University In The City Of New York Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide
CA2457885A1 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030219854A1 (en) * 2002-03-21 2003-11-27 Micrologix Biotech Inc. Methods for producing modified anti-infective peptides
EP1497327A2 (en) * 2002-04-17 2005-01-19 Novartis AG Method for the identification of inhibitors of the binding of are-containing mrna and an hur protein
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
AU2003231471A1 (en) * 2002-04-25 2003-11-10 Toagosei Co., Ltd. Antimicrobial polypeptide and utizliation thereof
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
SE0202613D0 (sv) * 2002-09-04 2002-09-04 Innate Pharmaceuticals Ab Förfarande och prob för identifiering av ämnen som modifierar bakteriers virulens, som sådana identifierade ämnen samt deras användning
US7238669B2 (en) * 2002-09-11 2007-07-03 The Curators Of The University Of Missouri Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae
US20050245582A1 (en) * 2002-09-12 2005-11-03 The Hartz Mountain Corporation High concentration topical insecticides containing pyrethroids
US20060276339A1 (en) * 2002-10-16 2006-12-07 Windsor J B Methods and compositions for increasing the efficacy of biologically-active ingredients
CA2514466C (en) 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
US20040260454A1 (en) * 2003-06-11 2004-12-23 Basir Otman A. Vibro-acoustic engine diagnostic system
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
US20050171063A1 (en) * 2003-10-20 2005-08-04 Pawan Malhotra Use of phosphono derivatives as anti-malarials
WO2005039557A1 (en) * 2003-10-22 2005-05-06 Council Of Scientific And Industrial Research Use of selected amino acid-zinc complexes as anti-malarial
EP1688486B1 (en) * 2003-10-29 2016-12-14 Toagosei Co., Ltd. Antibacterial peptide and utilization of the same
JP2008500965A (ja) * 2004-03-17 2008-01-17 エムペックス・ファーマシューティカルズ・インコーポレーテッド 細菌の排出ポンプ阻害剤の使用および投与
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US20050282755A1 (en) * 2004-03-18 2005-12-22 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
PT1773878E (pt) 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
JP4507080B2 (ja) * 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
US7588885B2 (en) * 2004-08-06 2009-09-15 Chung Yuan Christian University Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation
US20060068020A1 (en) * 2004-09-24 2006-03-30 Cottrell Ian W Encapsulated pharmaceutical agents
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
US20090030179A1 (en) * 2005-02-15 2009-01-29 Toagosei Co., Ltd Antimicrobial peptide and use thereof
WO2007014372A2 (en) 2005-07-28 2007-02-01 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
US8207295B2 (en) * 2008-06-04 2012-06-26 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
JP2011195451A (ja) * 2008-06-20 2011-10-06 Fukuoka Univ ペプチド
US8773662B2 (en) * 2010-07-22 2014-07-08 Vuv Analytics, Inc. Methods and apparatus for vacuum ultraviolet (VUV) or shorter wavelength circular dichroism spectroscopy
DK2600869T3 (da) * 2010-08-05 2020-11-16 Helperby Therapeutics Ltd Kombination af en pyrroloquinolinforbindelse og et beta-lactam-antimikrobielt middel, mupirocin eller chlorhexidin
CN102167731B (zh) * 2011-02-10 2013-01-23 周逸明 一种固相多肽合成奥米加南的制备方法
WO2013056003A2 (en) 2011-10-12 2013-04-18 Yale University Catechol diethers as potent anti-hiv agents
WO2015038660A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015077057A1 (en) * 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
RU2678985C2 (ru) * 2017-02-06 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Биоцидный пептид и препарат на его основе
CN108721292B (zh) * 2018-05-04 2022-04-01 中国疾病预防控制中心病毒病预防控制所 扑蛲灵在制备广谱抗冠状病毒药物中的应用
US12383700B2 (en) 2019-06-13 2025-08-12 Hollister Incorporated Reusable urinary catheter products
EP4628107A3 (en) 2019-06-25 2025-12-17 Hollister Incorporated Reusable urinary catheter products
KR102433665B1 (ko) * 2021-11-17 2022-08-19 주식회사 씨위드 인돌리시딘 유래 항균 펩타이드 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
US5547939A (en) 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
NZ275205A (en) 1993-09-22 1998-03-25 Xoma Corp Use of bactericidal/permeability-increasing protein in treating gram-negative bacterial infection
JP4076026B2 (ja) * 1993-10-25 2008-04-16 トランセイヴ，インコーポレイテッド リポソームディフェンシン
DK0754050T3 (da) 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US5877274A (en) 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
AU6940796A (en) 1995-08-23 1997-03-19 University Of British Columbia, The Antimicrobial cationic peptides and methods of screening for the same
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
WO1999043357A1 (en) 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers

Also Published As

Publication number Publication date
CA2263799A1 (en) 1998-02-26
HK1021824A1 (en) 2000-07-07
EP0925308B1 (en) 2002-06-05
HK1043475A1 (en) 2002-09-13
JP2005225857A (ja) 2005-08-25
US6180604B1 (en) 2001-01-30
US20080242614A1 (en) 2008-10-02
US20040009910A1 (en) 2004-01-15
DE69739035D1 (de) 2008-11-20
DE69713112T2 (de) 2003-01-30
JP4073900B2 (ja) 2008-04-09
ATE218579T1 (de) 2002-06-15
WO1998007745A2 (en) 1998-02-26
WO1998007745A3 (en) 1998-07-09
DE69713112D1 (de) 2002-07-11
US7390787B2 (en) 2008-06-24
HK1043475B (en) 2009-07-03
US6538106B1 (en) 2003-03-25
ATE410441T1 (de) 2008-10-15
EP0925308A2 (en) 1999-06-30
JP2001500477A (ja) 2001-01-16
ES2315252T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
EP0720482A4 (en) PROSAPOSIN AND CYTOKIN-DERIVED PEPTIDES AS THERAPEUTIC ACTIVE SUBSTANCES
BR9708911A (pt) Composto fragmento de peptídeo processo par tratar uma doença em um paciente em necessidade de terapia antioangiogênese composição polinucleotídeo único ou de duplo-filamento isolado vetor e processo para produzir um fragmento de peptídeo de kringle 5 ou proteína de fusão de kringle 5 solúvel
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
WO2002048183A3 (en) Compositions of peptide crystals
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
MX9301457A (es) Agentes antifungicos de peptidos ciclicos y proceso para su preparacion.
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
HUT62916A (en) Process for producing immunogenic peptides and pharmaceutical compositions comprising same
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
ES2180948T3 (es) Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal.
DK525384D0 (da) Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
DE69735583D1 (de) Semisynthetisches verfahren zur herstellung von didemninanalogen
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
PT938329E (pt) Composicao de tlp imunogenica
PL351376A1 (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines